Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw

Beatrice J. Edwards, Mrinal Gounder, June M. McKoy, Ian Boyd, Mathew Farrugia, Cesar Migliorati, Robert Marx, Salvatore Ruggiero, Meletios Dimopoulos, Dennis W. Raisch, Seema Singhal, Ken Carson, Eniola Obadina, Steve Trifilio, Dennis West, Jayesh Mehta, Charles L. Bennett

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

More than half of all serious adverse reactions are identified 7 or more years after a drug receives approval from the US Food and Drug Administration (FDA). In 2002, 9 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketing, the FDA received reports of nine patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosis of the jaw. During the next 2 years, three oral surgeons described 104 patients with cancer with osteonecrosis of the jaw in the medical literature and identified intravenous bisphosphonate therapy as being common to the care of these patients. In subspecialty medical, radiology, and dental journals, case reports and case series described clinical features of osteonecrosis of the jaw in patients with cancer who were treated with bisphosphonates. Manufacturer-sponsored epidemiological studies reported the first estimates of the incidence of this toxic effect, ranging from 0·1% to 1·8%. By contrast, independent epidemiological efforts from clinicians and the International Myeloma Foundation reported incidence estimates between 5% and 10%. Between 2003 and 2005, warnings about the risks of bisphosphonate-associated osteonecrosis were disseminated by national regulatory agencies, the manufacturers of bisphosphonates, and the International Myeloma Foundation. From 2006, independent clinical recommendations for diagnosis, prevention, and treatment of this toxic effect have been disseminated by manufacturers, national regulatory authorities, the International Myeloma Foundation, and medical specialty organisations. Furthermore, independent efforts by pharmaceutical manufacturers, dental and medical professionals, a non-profit organisation (the International Myeloma Foundation), patients, and regulatory authorities has led to the rapid identification and dissemination of safety information for this serious adverse reaction. Better coordination of safety-related pharmacovigilance initiatives is now needed.

Original languageEnglish (US)
Pages (from-to)1166-1172
Number of pages7
JournalThe Lancet Oncology
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2008

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Pharmacovigilance
zoledronic acid
Diphosphonates
United States Food and Drug Administration
Jaw
Osteonecrosis
Poisons
Tooth
Nonprofit Organizations
Drug Approval
Safety
Neoplasms
Information Dissemination
Incidence
Marketing
Radiology
Epidemiologic Studies
Patient Care
Medicine

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Edwards, B. J., Gounder, M., McKoy, J. M., Boyd, I., Farrugia, M., Migliorati, C., ... Bennett, C. L. (2008). Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. The Lancet Oncology, 9(12), 1166-1172. https://doi.org/10.1016/S1470-2045(08)70305-X

Pharmacovigilance and reporting oversight in US FDA fast-track process : bisphosphonates and osteonecrosis of the jaw. / Edwards, Beatrice J.; Gounder, Mrinal; McKoy, June M.; Boyd, Ian; Farrugia, Mathew; Migliorati, Cesar; Marx, Robert; Ruggiero, Salvatore; Dimopoulos, Meletios; Raisch, Dennis W.; Singhal, Seema; Carson, Ken; Obadina, Eniola; Trifilio, Steve; West, Dennis; Mehta, Jayesh; Bennett, Charles L.

In: The Lancet Oncology, Vol. 9, No. 12, 01.12.2008, p. 1166-1172.

Research output: Contribution to journalReview article

Edwards, BJ, Gounder, M, McKoy, JM, Boyd, I, Farrugia, M, Migliorati, C, Marx, R, Ruggiero, S, Dimopoulos, M, Raisch, DW, Singhal, S, Carson, K, Obadina, E, Trifilio, S, West, D, Mehta, J & Bennett, CL 2008, 'Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw', The Lancet Oncology, vol. 9, no. 12, pp. 1166-1172. https://doi.org/10.1016/S1470-2045(08)70305-X
Edwards, Beatrice J. ; Gounder, Mrinal ; McKoy, June M. ; Boyd, Ian ; Farrugia, Mathew ; Migliorati, Cesar ; Marx, Robert ; Ruggiero, Salvatore ; Dimopoulos, Meletios ; Raisch, Dennis W. ; Singhal, Seema ; Carson, Ken ; Obadina, Eniola ; Trifilio, Steve ; West, Dennis ; Mehta, Jayesh ; Bennett, Charles L. / Pharmacovigilance and reporting oversight in US FDA fast-track process : bisphosphonates and osteonecrosis of the jaw. In: The Lancet Oncology. 2008 ; Vol. 9, No. 12. pp. 1166-1172.
@article{89bcc70eb5be4ef79b9f8578522e2ecd,
title = "Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw",
abstract = "More than half of all serious adverse reactions are identified 7 or more years after a drug receives approval from the US Food and Drug Administration (FDA). In 2002, 9 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketing, the FDA received reports of nine patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosis of the jaw. During the next 2 years, three oral surgeons described 104 patients with cancer with osteonecrosis of the jaw in the medical literature and identified intravenous bisphosphonate therapy as being common to the care of these patients. In subspecialty medical, radiology, and dental journals, case reports and case series described clinical features of osteonecrosis of the jaw in patients with cancer who were treated with bisphosphonates. Manufacturer-sponsored epidemiological studies reported the first estimates of the incidence of this toxic effect, ranging from 0·1{\%} to 1·8{\%}. By contrast, independent epidemiological efforts from clinicians and the International Myeloma Foundation reported incidence estimates between 5{\%} and 10{\%}. Between 2003 and 2005, warnings about the risks of bisphosphonate-associated osteonecrosis were disseminated by national regulatory agencies, the manufacturers of bisphosphonates, and the International Myeloma Foundation. From 2006, independent clinical recommendations for diagnosis, prevention, and treatment of this toxic effect have been disseminated by manufacturers, national regulatory authorities, the International Myeloma Foundation, and medical specialty organisations. Furthermore, independent efforts by pharmaceutical manufacturers, dental and medical professionals, a non-profit organisation (the International Myeloma Foundation), patients, and regulatory authorities has led to the rapid identification and dissemination of safety information for this serious adverse reaction. Better coordination of safety-related pharmacovigilance initiatives is now needed.",
author = "Edwards, {Beatrice J.} and Mrinal Gounder and McKoy, {June M.} and Ian Boyd and Mathew Farrugia and Cesar Migliorati and Robert Marx and Salvatore Ruggiero and Meletios Dimopoulos and Raisch, {Dennis W.} and Seema Singhal and Ken Carson and Eniola Obadina and Steve Trifilio and Dennis West and Jayesh Mehta and Bennett, {Charles L.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/S1470-2045(08)70305-X",
language = "English (US)",
volume = "9",
pages = "1166--1172",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - Pharmacovigilance and reporting oversight in US FDA fast-track process

T2 - bisphosphonates and osteonecrosis of the jaw

AU - Edwards, Beatrice J.

AU - Gounder, Mrinal

AU - McKoy, June M.

AU - Boyd, Ian

AU - Farrugia, Mathew

AU - Migliorati, Cesar

AU - Marx, Robert

AU - Ruggiero, Salvatore

AU - Dimopoulos, Meletios

AU - Raisch, Dennis W.

AU - Singhal, Seema

AU - Carson, Ken

AU - Obadina, Eniola

AU - Trifilio, Steve

AU - West, Dennis

AU - Mehta, Jayesh

AU - Bennett, Charles L.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - More than half of all serious adverse reactions are identified 7 or more years after a drug receives approval from the US Food and Drug Administration (FDA). In 2002, 9 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketing, the FDA received reports of nine patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosis of the jaw. During the next 2 years, three oral surgeons described 104 patients with cancer with osteonecrosis of the jaw in the medical literature and identified intravenous bisphosphonate therapy as being common to the care of these patients. In subspecialty medical, radiology, and dental journals, case reports and case series described clinical features of osteonecrosis of the jaw in patients with cancer who were treated with bisphosphonates. Manufacturer-sponsored epidemiological studies reported the first estimates of the incidence of this toxic effect, ranging from 0·1% to 1·8%. By contrast, independent epidemiological efforts from clinicians and the International Myeloma Foundation reported incidence estimates between 5% and 10%. Between 2003 and 2005, warnings about the risks of bisphosphonate-associated osteonecrosis were disseminated by national regulatory agencies, the manufacturers of bisphosphonates, and the International Myeloma Foundation. From 2006, independent clinical recommendations for diagnosis, prevention, and treatment of this toxic effect have been disseminated by manufacturers, national regulatory authorities, the International Myeloma Foundation, and medical specialty organisations. Furthermore, independent efforts by pharmaceutical manufacturers, dental and medical professionals, a non-profit organisation (the International Myeloma Foundation), patients, and regulatory authorities has led to the rapid identification and dissemination of safety information for this serious adverse reaction. Better coordination of safety-related pharmacovigilance initiatives is now needed.

AB - More than half of all serious adverse reactions are identified 7 or more years after a drug receives approval from the US Food and Drug Administration (FDA). In 2002, 9 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketing, the FDA received reports of nine patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosis of the jaw. During the next 2 years, three oral surgeons described 104 patients with cancer with osteonecrosis of the jaw in the medical literature and identified intravenous bisphosphonate therapy as being common to the care of these patients. In subspecialty medical, radiology, and dental journals, case reports and case series described clinical features of osteonecrosis of the jaw in patients with cancer who were treated with bisphosphonates. Manufacturer-sponsored epidemiological studies reported the first estimates of the incidence of this toxic effect, ranging from 0·1% to 1·8%. By contrast, independent epidemiological efforts from clinicians and the International Myeloma Foundation reported incidence estimates between 5% and 10%. Between 2003 and 2005, warnings about the risks of bisphosphonate-associated osteonecrosis were disseminated by national regulatory agencies, the manufacturers of bisphosphonates, and the International Myeloma Foundation. From 2006, independent clinical recommendations for diagnosis, prevention, and treatment of this toxic effect have been disseminated by manufacturers, national regulatory authorities, the International Myeloma Foundation, and medical specialty organisations. Furthermore, independent efforts by pharmaceutical manufacturers, dental and medical professionals, a non-profit organisation (the International Myeloma Foundation), patients, and regulatory authorities has led to the rapid identification and dissemination of safety information for this serious adverse reaction. Better coordination of safety-related pharmacovigilance initiatives is now needed.

UR - http://www.scopus.com/inward/record.url?scp=56449103037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449103037&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(08)70305-X

DO - 10.1016/S1470-2045(08)70305-X

M3 - Review article

C2 - 19038763

AN - SCOPUS:56449103037

VL - 9

SP - 1166

EP - 1172

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 12

ER -